#EliLillyRises5.3%ToRecordHigh
Eli Lilly's move doesn't seem like just a stock rally to me. The company's recent Q2 results showed revenue up nearly 48% to $22.97 billion, with strong demand for Mounjaro and Zepbound playing a big role. At the same time, Lilly raised its 2026 revenue guidance to $85–87 billion. This combination seems to have boosted investor confidence. Despite competition in the GLP-1 drug market, Lilly is still in a pretty strong position.
Eli Lilly's move doesn't seem like just a stock rally to me. The company's recent Q2 results showed revenue up nearly 48% to $22.97 billion, with strong demand for Mounjaro and Zepbound playing a big role. At the same time, Lilly raised its 2026 revenue guidance to $85–87 billion. This combination seems to have boosted investor confidence. Despite competition in the GLP-1 drug market, Lilly is still in a pretty strong position.